Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial.
Nat Med. 2023 Dec;29(12):2985-2987. doi: 10.1038/s41591-023-02580-5.
Nat Med. 2023.
PMID: 37857712
No abstract available.
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply.
Pautier P, Tanguy ML, Archambaud B.
Pautier P, et al. Among authors: archambaud b.
Lancet Oncol. 2022 Oct;23(10):e445. doi: 10.1016/S1470-2045(22)00563-0.
Lancet Oncol. 2022.
PMID: 36174626
No abstract available.
Item in Clipboard
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.
Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, Pignot G, Gravis G, Helissey C, Campedel L, Roupret M, Xylinas E, Ouzaid I, Dubuisson A, Mazzenga M, Flament C, Ly P, Marty V, Signolle N, Sauvat A, Sbarrato T, Filahi M, Davin C, Haddad G, Bou Khalil J, Bleriot C, Danlos FX, Dunsmore G, Mulder K, Silvin A, Raoult T, Archambaud B, Belhechmi S, Gomperts Boneca I, Cayet N, Moya-Nilges M, Mallet A, Daillere R, Rouleau E, Radulescu C, Allory Y, Fieschi J, Rouanne M, Ginhoux F, Le Teuff G, Derosa L, Marabelle A, Van Dorp J, Van Dijk N, Van Der Heijden MS, Besse B, Andre F, Merad M, Kroemer G, Scoazec JY, Zitvogel L, Loriot Y.
Goubet AG, et al. Among authors: archambaud b.
Cancer Discov. 2022 Oct 5;12(10):2280-2307. doi: 10.1158/2159-8290.CD-22-0201.
Cancer Discov. 2022.
PMID: 35929803
Item in Clipboard
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group.
Pautier P, et al. Among authors: archambaud b.
Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11.
Lancet Oncol. 2022.
PMID: 35835135
Clinical Trial.
Item in Clipboard
Cite
Cite